APEXIGEN INC (APGN) Stock Overview
USA - NASDAQ:APGN - US03759B1026 - Common Stock
APGN Key Statistics, Chart & Performance
The current stock price of APGN is 0.3851 USD. In the past month the price decreased by -6.07%. In the past year, price decreased by -92.33%.
APGN Latest News, Press Relases and Analysis
APGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.55 | 403.13B | ||
| AMGN | AMGEN INC | 13.39 | 157.20B | ||
| GILD | GILEAD SCIENCES INC | 14.46 | 146.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.79 | 107.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.53 | 69.32B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 345.82 | 58.93B | ||
| ARGX | ARGENX SE - ADR | 61.91 | 50.51B | ||
| INSM | INSMED INC | N/A | 41.05B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.97 | 33.85B | ||
| NTRA | NATERA INC | N/A | 26.52B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| BIIB | BIOGEN INC | 8.94 | 21.93B |
Related stock screener links
About APGN
Company Profile
Apexigen, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in San Carlos, California and currently employs 20 full-time employees. The company went IPO on 2021-02-02. The firm is focused on discovering and developing antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient’s immune system to combat and eradicate cancer. The company has developed a clinical-stage candidate, namely sotigalimab (sotiga or APX005M), which is a humanized agonist antibody. The company also has various preclinical and research-stage antibodies it discovered using its APXiMAB platform. The company is focused on completing ongoing clinical and manufacturing activities for the sotiga program. The Company’s licensees are advancing five product candidates in clinical development that were enabled by discoveries from its APXiMAB platform. APX005M is under Phase II clinical development for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction cancers and melanoma, in combination with chemotherapy, radiation therapy and immunotherapy.
Company Info
APEXIGEN INC
900 Industrial Road, Suite C
San Carlos CALIFORNIA US
Employees: 20
Phone: 16509316236.0
APEXIGEN INC / APGN FAQ
What does APEXIGEN INC do?
Apexigen, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in San Carlos, California and currently employs 20 full-time employees. The company went IPO on 2021-02-02. The firm is focused on discovering and developing antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient’s immune system to combat and eradicate cancer. The company has developed a clinical-stage candidate, namely sotigalimab (sotiga or APX005M), which is a humanized agonist antibody. The company also has various preclinical and research-stage antibodies it discovered using its APXiMAB platform. The company is focused on completing ongoing clinical and manufacturing activities for the sotiga program. The Company’s licensees are advancing five product candidates in clinical development that were enabled by discoveries from its APXiMAB platform. APX005M is under Phase II clinical development for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction cancers and melanoma, in combination with chemotherapy, radiation therapy and immunotherapy.
What is the stock price of APEXIGEN INC today?
The current stock price of APGN is 0.3851 USD. The price increased by 8.48% in the last trading session.
Does APGN stock pay dividends?
APGN does not pay a dividend.
What is the ChartMill rating of APEXIGEN INC stock?
APGN has a ChartMill Technical rating of 0 out of 10.You can find more details on the Technical Analysis and Fundamental Analysis tabs.
How many employees does APEXIGEN INC have?
APEXIGEN INC (APGN) currently has 20 employees.
APGN Technical Analysis
APGN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
APGN Forecast & Estimates
6 analysts have analysed APGN and the average price target is 0.65 USD. This implies a price increase of 69.51% is expected in the next year compared to the current price of 0.3851.